A Patients' Perspective Towards the Injection Devices for Humira® and Imraldi® in a Nationwide Switching Program

The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures

(2021) Evelien Moorkens et al.   Frontiers in Pharmacology

The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence

(2020) Brian G. Feagan et al.   ADVANCES IN THERAPY

Evaluation of Adherence and Persistence Differences Between Adalimumab Citrate-Free and Citrate Formulations for Patients with Immune-Mediated Diseases in the United States

(2020) Martin Bergman et al.   Rheumatology and Therapy

Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?

(2019) Daniel C. Baumgart et al.   Frontiers in Pharmacology

Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes

(2018) Hillel P. Cohen et al.   DRUGS

State of the art paper Tumor necrosis factor inhibitors – state of knowledge

(2015) Krzysztof Lis et al.   Archives of Medical Science